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Cardiac pacemakers, implantable cardioverter-defibrillators, 
and electrode catheter systems are essential for the treatment 
of patients with cardiac arrhythmias. The widespread and 
rapidly expanding use of these antiarrhythmic devices has 
focused attention on the need for thorough, efficient, and 
practical assessment of their safety, efficacy, and clinical use- 
fulness. In general, the effectiveness of these devices is well 
documented. Their capabilities may be enhanced through 
incorporation of existing technology and future innovations, 
and it is anticipated that the range of clinical indications 
requiring intervention and the demand for use of antiarrhyth- 
mic devices will continue to grow. 
A multidisciplinary policy conference was held November 
15 and 16, 1993, in Washington, DC, to facilitate formal 
communication among interested parties involved in the de- 
velopment and use of antiarrhythmic devices. Participants 
included representatives of divisions of the Food and Drug 
Administration (FDA) responsible for overseeing the pre- 
market release valuation and post-market release surveillance 
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of antiarrhythmic devices and the Health Industry Manufac- 
turers Association, representing the device manufacturing 
industry. 
This statement focuses on the types of clinical evaluation 
necessary for commercial release and subsequent assessment 
of antiarrhythmic devices. Generally, the term clinical investi- 
gation describes the broad area of scientific studies pertaining 
to human pathophysiology and therapeutics. In this report, the 
term clinical evaluation refers to a specific lass of clinical 
investigations performed as part of a government-mandated 
biomedical regulatory mission (Fig 1). 
This statement is based on a consensus ofa joint task force 
comprising physicians and other healthcare professionals rep- 
resenting the North American Society of Pacing and Electro- 
physiology, the American College of Cardiology, the American 
Heart Association, and the Working Groups on Arrhythmias 
and Pacing of the European Society of Cardiology. The FDA 
and the Health Industry Manufacturers Association provided 
the task force with information and recommendations. This 
report also describes the essential elements of clinical evalua- 
tions to assess the safety, efficacy, and clinical performance of
antiarrhythmic devices as proposed by the task force. 
Diagnostic and therapeutic advances inthe performance of
antiarrhythmic devices are often incremental nd based on a 
well-developed foundation of knowledge. There is a large body 
of technical and clinical experience regarding implantable 
antibradycardia pacing systems. Most recent developments 
represent incremental improvements in sophistication and 
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Figure l. Schematic diagram showing the relation between different 
types of clinical investigation u dertaken in development of an anti- 
arrhythmic device, its clinical application, and its commercial release. 
The phases of clinical evaluation a d subsequent process are detailed 
at left. Other clinical investigations performed for scientific nquiry are 
delineated at right. Interrelations between the two processes and their 
relations to practice guidelines, outcomes research, clinical usefulness, 
and post-marketing studies are broadly presented. 
physiological operation. The circumscribed nature of such 
improvements should be considered when device performance 
is evaluated. When a major therapeutic innovation or clinical 
application of emerging technology is proposed, the clinical 
evaluation may be broader and the investigative r quirements 
more rigorous. 
Significant differences exist between the investigation of 
antiarrhythmic drugs and the investigation of antiarrhythmic 
devices: there can be no blinding in a study of devices; it is 
usually far more difficult o withdraw a device than a drug; a 
surgical procedure that incurs some degree of morbidity and 
mortality isoften required for implantation fa device; devices 
may be more expensive initially than drugs; and some current 
devices may not prevent cardiac arrhythmias but only treat 
recurrences. Because of these concerns, considerable medical 
and technical expertise is required to design the appropriate 
clinical evaluation. A clear understanding of the clinical impli- 
cations associated with proposed changes in a device or new 
concepts is crucial to optimize assessment and foster innova- 
tion, thus ultimately bringing technological dvances to the 
patient in a timely, cost-effective manner. 
The task force recognizes that clinical investigation of 
antiarrhythmic devices encompasses two distinct processes: (1) 
clinical evaluation (regulatory process) to ascertain the safety 
and efficacy of a proposed evice or change in a device for a 
given use and (2) clinical research initiated by the medical 
community and aimed at establishing the nature and extent of 
medical benefit associated with the development of a device 
(Fig 1). The latter process may be initiated before, during, or 
after the regulatory process. Often, however, medically di- 
rected trials continue throughout the useful ife of a device and 
at any point may affect the regulatory issue of device "label- 
ing," a process based on the presentation of sound medical 
evidence in which national or international regulatory bodies 
determine a formal indication (or modify an existing indica- 
tion) for specific linical application of a device. 
A major goal of the task force is to define the device 
evaluation process in the context of optimal care of the patient 
with arrhythmia. Crucial to achieving this goal are promotion 
of trust among physicians, regulators, and manufacturers and 
recognition that realistic solutions to complex problems re- 
quire flexibility based on reasonable medical and scientific 
judgment. To this end, physicians hould clearly define the 
critical medical issues associated with investigation ofa partic- 
ular device. Furthermore, the task force recommends consid- 
eration of appropriately collected and validated information 
regarding the device and its uses. Physicians and manufactur- 
ers recognize that regulatory agencies have an obligation to 
assess the safety and efficacy of a device. Physicians eek 
unbiased, well-founded recommendations regarding the im- 
portant medical/scientific issues that need to be addressed 
during clinical evaluation of an antiarrhythmic device. Manu- 
facturers need efficient, medically realistic, and predictable 
guidelines for clinical evaluation, with feasible study end 
points. All are concerned with the ethics of biomedical inves- 
tigation, as well as innovative, cost-effective health care and 
increased research opportunities. This statement presents a
general framework for facilitating efficient, scientific assess- 
ment of current and evolving antiarrhythmic devices, spe- 
cifically, cardiac pacemakers, implantable cardioverter- 
defibrillators, and electrode catheter systems. 
Phases of Clinical Investigation 
The goal of all clinical investigative studies of antiarrhyth- 
mic devices is to characterize their proper clinical application. 
The design of these studies reflects many factors related to the 
device, the patient, the medical team, therapeutic alternatives, 
and the risk-benefit ratio. Clinical investigation i cludes re- 
search to test specific hypotheses and clinical evaluation of 
device performance for regulatory approval (Fig 1). Clinical 
evaluation studies are as scientifically rigorous as other clinical 
research but are directed at fulfilling the regulatory mission. 
Evaluation studies are designed to ensure reasonable safety 
and efficacy and are supplemented with regulatory post-market 
release surveillance studies. The proposed phases of clinical 
evaluation studies are outlined in Fig. l. Completion of these 
phases is followed by regulatory review and recommendations 
related to commercial release. 
Technological development is an evolutionary process and 
has a natural history. Depending on the nature of the device 
and the results of early studies, the evolution of new technol- 
ogy may take different courses. The time periods when differ- 
ent types of investigations are undertaken i  the life cycle of a 
device also vary. Clinical evaluation studies of devices fall into 
three broad categories: the pilot study, the main study deter- 
mining commercial release, and postmarketing safety surveil- 
lance. The rationale for these categories i  that the goals of 
each type of study can differ markedly. 
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In general, after conception and early development of a 
new technology, preclinical testing takes place, followed by a 
limited-scale clinical feasibility or pilot study conducted at 
a small number of sites. The overall goal of pilot studies is to 
demonstrate the clinical feasibility of a new device and proto- 
col, as well as provide an estimate of its short-term safety and 
efficacy. A relatively small number of patients from a few 
centers are enrolled in these studies, which may or may not be 
randomized. Pilot studies are needed to identify major toxicity 
and potentially serious problems at an early stage and to 
determine whether there is sufficient efficacy to justify proceed- 
ing with the main study. Pilot studies also provide an invaluable 
opportunity for refining the device and protocol. This phase is 
particularly important for investigators to acquire new skills 
needed in application of the procedure and to identify unfore- 
seen problems, for example, in study design. Duration of a 
pilot study is governed by the time needed to resolve unantic- 
ipated complications, inefficacy, or issues of safety. The pilot 
phase may be brief (eg, no technical skills must be learned) or 
protracted (eg, unanticipated problems occur or technical 
skills needed to use the device are difficult o learn). Embark- 
ing on a large-scale clinical evaluation prematurely can yield 
misleading data on the true usefulness and efficacy of a device. 
Technical difficulties hould be corrected before concluding 
that the device or procedure is seriously flawed. 
The main study for clinical evaluation of a device should be 
comprehensive and designed to provide more extensive long- 
term evidence of safety and efficacy. The type of study under- 
taken depends on the research question under investigation. 
Clinical evaluation studies may seek to demonstrate either 
superiority or equivalence of a particular technology with 
respect o existing options. Other types of clinical investiga- 
tions (shown as other clinical research in Fig 1) may test other 
specific hypotheses. A study should have one major hypothesis, 
but a number of secondary hypotheses may also be tested 
within one clinical investigation. 
After commercial release, surveillance studies are needed 
to determine if adverse ffects that may be attributable to the 
device exist that were not recognized in preapproval studies. 
During this phase, other clinical questions can also be addressed, 
including quality of life and cost. These issues may sometimes 
be the primary or secondary end points of preapproval studies. 
Clinical outcomes research is best performed after market 
release of a device to establish guidelines for its use in medical 
practice. Innovations in use of a device, combining approved 
components from different manufacturers or systems to form a 
hybrid system, may benefit individual patients. Alternatively, 
there may be "orphan" indications for a device. In these 
instances, follow-up data collection and scientific examination 
are still required. Clinical utility of an antiarrhythmic device is 
determined by the therapeutic significance of clinical research 
results, based on data generated from clinical evaluation 
studies, other clinical research, post-market release surveil- 
lance data, outcomes research, and registry/database analyses. 
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Figure 2. Relation between technology evolution and clinical indica- 
tions with respect to types of clinical evaluation appropriate for 
antiarrhythmic device studies. Study design relative to specific atego- 
ries shown in this figure is discussed in the text. Both evolving 
technology and indications are classified as novel or an incremental 
evolution with respect to existing status. 
Principles of Clinical Evaluation of 
Antiarrhythmic Devices 
The regulatory approval process must ensure that devices 
for which marketing approval is sought are safe and effective 
for their intended use. Clinical evaluation studies designed to 
establish safety and efficacy must demonstrate that the device 
is at least as effective and safe as the existing standard treat- 
ment or that it provides a benefit, compared with the natural 
history of the disease. As a result, in clinical evaluation studies 
offered for regulatory approval, adevice is generally compared 
with either the current standard or no treatment. A variety of 
study designs can be considered when selecting the appropriate 
evaluation process. In any study conducted for such a purpose, 
informed patient consent is essential. The patient-consent 
form should include all elements for well-informed patient 
participation, 
Selection of Study Design 
A study design matrix suggesting the clinical evaluation 
necessary to assess the function and therapeutic implications of 
specific device innovations is presented in Fig. 2. Device 
innovations for which only limited clinical evaluation may be 
necessary for regulatory purposes include those that do not 
alter efficacy and probably do not alter safety. Such innovations 
may be assessed inpart by "bench" testing. Device innovations 
that are evolutionary in ease of use but unaltered in basic 
function (category A in Fig 2) generally should not require a 
randomized clinical trial. Innovative devices that expand indi- 
cations for use or are technologically distinct imply greater 
benefits, greater isks, and greater uncertainty; they may be 
used for existing or new indications (categories B and D 
respectively in Fig 2). Comprehensive clinical evaluation is 
necessary to establish efficacy, safety, and appropriate labeling. 
Comprehensive trials are also needed for approval of applica- 
tions of existing or evolutionary technology for a new indica- 
tion (category C); either randomized or observational study 
designs may be used. 
In a randomized clinical trial patients are assigned to 
treatment or comparison groups by chance. Randomization 
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reduces the potential for bias, resulting in study groups that are 
more likely to be comparable. Importantly, randomization also 
ensures that it is mathematically appropriate to use statistical 
analysis. The randomized clinical trial is the most scientifically 
rigorous approach to comparing treatments. It is also usually 
the most resource- and time-intensive approach. The standard 
used for comparison may be current reatment of the disease 
or its natural history if there is no effective treatment. In any 
clinical trial, it is ethical to randomly assign patients to 
different study groups if two or more treatments are available 
but it is not known which of the treatments is more effective. 
An observational study of treatment effect is reasonable only 
when the natural history of the disease is well characterized, 
(for instance, cardiac arrest unresponsive to advanced cardiac 
life support). For historical controls to be useful, there should 
have been no significant change in the natural history of the 
disease or the effectiveness of therapies other than those under 
evaluation. A randomized clinical trial is not needed when the 
treatment effect is large or the natural history of the disease is 
well characterized, as in the cardiac arrest example. It is also 
not needed when the difference between the device for which 
approval is sought and the existing device is only an engineer- 
ing modification that does not fundamentally change the 
interaction of the device with a biological system, for example, 
the addition of improved telemetry capability to an implant- 
able defibrillator. 
In clinical evaluations a randomized clinical trial is most 
appropriate for investigating novel technology or new indica- 
tions for previously approved evices (categories B, C, and D 
in Fig 2). Randomized clinical trials are usually needed to show 
superiority of novel technology. Small, nonrandomized trials 
are unlikely to detect aclinical difference when there are minor 
changes in previously approved technology (category A in Fig 
2). In this latter situation, clinical evaluation may be designed 
to establish equivalence of therapies. An equivalency study has 
a hypothesis that is compatible with a one-sided statistical test 
such as the t test, ie, "device A is no worse than device B, for 
the end point of X." For purposes of equivalence, there also 
must be a priori agreement concerning the magnitude of an 
"important" difference in study end points, referred to as 
"tolerance." The study population and its expected event rate 
must be well characterized. These factors will have a major 
impact on sample size. Under some circumstances, a compar- 
ative trial may not be needed. 
It is proposed that a randomized clinical trial is needed for 
clinical evaluation studies when 
The device delivers energy to the patient in a fashion 
different from a device approved for the same or a similar 
indication, for example, a new mechanism of myocardial 
stimulation by an implantable pacemaker. 
• The device is used in an anatomical location that signif- 
icantly alters its functional outcome from its current use, 
for example, use of a defibrillator for atrial rather than 
ventricular arrhythmia management. 
A new indication is sought for a device; for example, 
validating the use of diagnostic information yielded by 
the device for making atreatment decision, such as use of 
an ultrasound array on a catheter to guide ablation 
before understanding the usefulness of such images. 
In studies designed for regulatory approval, the sponsor 
must demonstrate hat intervention with the device either 
favorably alters the natural history of the disease (if there is no 
current reatment), improves quality of life without an adverse 
effect on survival, or produces an effect at least as beneficial as 
the current standard of therapy. If the treatment is demonstra- 
bly better than the current standard, approval is highly prob- 
able. If there is a difference, then its magnitude must be 
examined to determine if it is clinically relevant, ie, what 
tolerance is acceptable. This question defines tudy design in 
terms of sample size and cost and time needed to implement 
the study and requires a clinical judgment. These concerns 
about sample size apply equally to randomized clinical trials 
and studies in which a comparison is made to a known 
standard. It should be emphasized that a randomized clinical 
trial is not necessarily a larger trial. Instead, the size of the trial 
determines the minimum tolerance that can be resolved by the 
study. These guidelines provide a reasonable framework for 
deciding what type of study is appropriate for a given device 
and/or indication but do not eliminate the need for medical 
judgment. 
Clinical Evaluation Studies: Structure and Analysis 
These studies should be expeditious and conducted with 
both scientific rigor and realism. They should be designed by a 
planning committee whose members possess the appropriate 
expertise, including the regulatory agency staff, its medical 
experts, and outside consultants. A data and safety monitoring 
board and an end point (events) committee should also be 
involved in the studies. Interim analyses using appropriate 
statistical monitoring techniques are recommended to elicit 
efficacious outcomes. With careful planning and coordination, 
appropriately documented positive results from such studies 
should lead to rapid and expeditious commercial release of the 
device. During the time between completion and analysis of 
the main study and commercial release, the new device should 
be available for use under the provisions of the investigative 
device xemption and approved protocol at existing study sites. 
Selection of an appropriate control or comparison group 
for the main study is critical. An important function of the 
planning committee should be to define the comparison group 
(eg, historical, concurrent, or randomized) on an individual 
basis. The characteristics of the two groups being compared 
should be similar. While randomization is the best way to 
achieve comparability, it may not always be feasible or neces- 
sary, and appropriate statistical adjustments may be needed to 
ensure comparability. 
The planning committee should categorize the device as 
either novel (ie, innovative) or evolutionary (ie, marginally 
changed) as shown in Fig. 2. Novel technology should be 
compared with the current standard, and randomization may 
be feasible; evolutionary technology may not require compar- 
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ison with the standard, and randomization to a standard or new 
device may not be feasible or necessary. When the novel 
feature can be programmed "on" or "off," consideration 
should be given to a randomized crossover design within the 
same patient group. 
Easily evaluated end points such as total mortality are 
generally the most suitable for objective analysis. In other 
instances, this end point may not be appropriate, for example, 
if the primary purpose of a device is other than to prolong life. 
Approval of devices that are intended to improve quality of life 
or prevent morbidity requires alternative measurements. In- 
clusion of quality-of-life measures i  an important milestone in 
the evolution of device research. Measurement of end points in 
this domain should reflect baseline measures to control for 
existing psychosocial nd functional status that may confound 
subsequently obtained quality-of-life measures. This approach 
is recommended to decrease the problem of falsely attributing 
causation to device technology. In each phase of the clinical 
investigation, it is essential to obtain patients' perceptions of 
the device and recovery from implantation. The selection of 
end points for clinical evaluation of a device should follow the 
same principles as those for any clinical investigation. 
When the usefulness of a device involves very few patients, 
the term orphan technology may be applied. Because commer- 
cial impact may be relatively small, the cost of bringing such 
devices through the regulatory process may be prohibitive. The 
task force believes these concerns could be addressed in the 
regulatory process by two different approaches. Tolerance, as 
defined above, could be sufficiently acceptable to justify a 
modest-sized study. Alternatively, governmental support of the 
clinical evaluation process would be needed. 
It is recommended that the study sponsor and representa- 
tives of the regulatory agency discuss the prospective clinical 
evaluation of a device. Such a discussion can define the 
appropriate study design for a given application and reason- 
able tolerance l vel(s) given the likely event rate(s). In making 
these decisions it is necessary to provide reasonable assurance 
of safety and efficacy without inhibiting innovation critical to 
improvements in patient care. 
Clinical Evaluation of Cardiac 
Pacing Systems 
Review of Past Guidelines 
Since 1976 there have been several types of FDA submis- 
sions by device manufacturers, including pre-market release 
notification, investigational device exemption, pre-market ap- 
proval, pre-market release approval supplement, and post- 
market release surveillance reports. Guidelines for clinical 
evaluation of pacemakers were initially proposed in 1983. In 
the intervening 12 years, clinical studies have been conducted 
and pre-market release approval has been granted for the 
addition of dual-chamber (atrial and ventricular) sequential 
pacing capability, single- and dual-chamber rate response, and 
physiological sensors. The North American Society of Pacing 
and Electrophysiology (NASPE) guidelines uggested that 30 
devices be implanted for 90 days and an additional 70 devices 
be implanted for 30 days. In some cases (eg, for the addition of 
physiological sensors), the sample sizes were slightly increased 
to accommodate physiological testing, but the initial 100 
dex.ices were adequate to provide clinical and statistical evi- 
dence of the functional effectiveness and safety of the device. 
Although the 1983 NASPE guidelines proved valuable, it is 
now apparent that clinical evaluation study requirements may 
need to be more rigorous in some circumstances. Ultimately, 
the clinical evaluation study must be capable of demonstrating 
relative safety and effectiveness (equivalent or superior) of the 
bradycardia pacing device in terms of the patient population 
for which its use is intended. The extent of the clinical study 
necessary depends on the balance between the degree of 
technical and clinical innovation, potential for risk to the 
patient, and potential for benefit o the patient. When analyz- 
ing patient risk, an essential component is any change that may 
be imposed on the most important functions of a pacemaker, 
ie, bradycardia support and sensing of spontaneous cardiac 
activity. These primary functions hould be differentiated from 
diagnostic features uch as event counters and other passive 
device characteristics. 
Recommended Clinical Evaluation Studies for 
Cardiac Pacemakers 
Minimal or no clinical evaluation is necessary for pacemak- 
ers and pacing systems derived from previously approved and 
thoroughly tested pacing systems that have undergone defea- 
turing. (Defeaturing refers to software-based "lockout" of an 
existing nonessential function.) Bench tests should confirm 
that the device functions within specifications. 
Limited clinical evaluation of a new feature is required 
(without reevaluation of the older, previously approved evice 
hardware or software) for devices with passive diagnostic 
features, temporary therapeutic features, or permanent on- 
essential features with minor therapeutic mplications. How- 
ever, the devices are essentially identical to the parent device 
in basic pacing and sensing functions. Rigorous bench testing 
of temporary functions, diagnostic features, and permanent 
nonessential features i  performed before the device is intro- 
duced clinically. Thus, evaluation should consist of limited 
clinical observation of the specific feature in action. Accept- 
able studies in addition to bench testing include (1) acute 
testing in limited numbers of patients, (2) testing the accuracy 
of diagnostic features against a standard, and (3) observation 
of the feature in action. Examples of such device modifications 
include activation of new diagnostic or temporary therapeutic 
features in an existing unit without a software or hardware 
change, and addition of rate-adaptive atrioventricular delay or 
rate-adaptive post-ventricular/atrial efractory period. 
An extensive clinical evaluation is needed when a change in 
a previously approved evice may affect its essential functions. 
Such a change is defined as a substantial or novel change. 
Examples of such devices include first-time design of a brady- 
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cardia pacemaker by a manufacturer using newly developed 
technology and a new single sensor for rate-adaptive pacing. 
In studies to evaluate such devices, a control group or a 
crossover design with the novel feature activated or deacti- 
vated may be used, with the study group as its own control. 
Alternatively, observational studies with well-characterized 
historical controls may be used. Because the safety and efficacy 
of many standard cardiac pacemakers is well known, historical 
controls are acceptable in some instances, eg, a first-time 
design of a new bradycardia pacemaker. The goals of these 
studies are based on the expected or desired claims made for 
the product. However, unless a manufacturer claims superior- 
ity for a specific device, the goal of these studies hould be to 
show equivalence with standard therapy. 
A randomized clinical trial generally should be performed 
for previously approved or novel types of devices being evalu- 
ated for a new clinical indication for purposes of device 
labeling (categories C and D in Fig 2). These clinical studies 
may occur at any time after the initial commercial release of a 
specific pacemaker. Specific examples where these guidelines 
may apply include DDD-pacing in idiopathic hypertrophic/ 
dilated cardiomyopathy or DDD/AAI pacing to prevent atrial 
fibrillation. Patients receiving a standard therapy should serve 
as the control. Crossover or parallel designs may also be used 
in such studies. Historical controls may be appropriate when 
the natural history of a particular disease is well known. 
Investigators must recognize that when two different pacing 
modes or options are tested in parallel study, research subjects 
who have received implants of the older device (the control 
group) cannot easily change to the improved evice at the end 
of the study. This is in marked contrast with most pharmaceu- 
tical studies where, at the end of the study, the control group 
is easily switched to the most beneficial therapy. Thus, to 
protect subjects in the experimental group, the ability to 
activate or deactivate he test feature on either a short- or long- 
term basis should be incorporated into the study design 
whenever possible. 
Primary and secondary end points must be clinically rele- 
vant and prospectively selected. Mortality should always be 
reported but may not be the primary end point for all clinical 
studies. Other appropriate clinical end points to define new 
indications for cardiac pacemakers may include nonfatal ar- 
rhythmias, such as atrial fibrillation; quality of life, us- 
ing standard, validated instruments; or relevant physiological 
parameters. 
Long-term Surveillance 
After approval of any pacemaker or pacing system, post- 
market release surveillance studies are indicated to determine 
whether any adverse ffects develop that were not apparent 
during the preapproval phase. Long-term surveillance has 
previously been based on manufacturers' registries of returned 
equipment or voluntary participation by multiple clinical cen- 
ters. Recent action by regulatory authorities has increased 
manufacturers' esponsibilities in monitoring the safety and 
efficacy of their systems or devices. However, the task force 
favors the maintenance of a multicenter registry with reporting 
mechanisms separate from those maintained by manufacturers. 
Clinical Evaluation of Implantable 
Cardioverter-Defibrillators 
Evolution of lmplantable 
Cardioverter-Defibrillator Therapy 
Implantable cardioverter-defibrillators have gone through a
striking technological evolution, with widespread therapeutic 
application within a decade of their clinical introduction. The 
growing maturity of the field is reflected in the recent adoption 
of a generic function code (NASPE/British Pacing and Elec- 
trophysiology Group defibrillator code) comparable to that 
used for pacemakers. Third-generation (or "tiered therapy") 
devices capable of providing energy-efficient shocks (biphasic 
waveforms), antitachycardia p cing, and backup VVI pacing 
have already been released commercially. The advent of 
transvenous electrode systems has reduced surgical mortality. 
In addition, the recommendations f the American College of 
Cardiology and NASPE address clinical indications in malig- 
nant ventricular arrhythmias. Comparative trials with pharma- 
cotherapy are in progress. Studies are also under way to 
evaluate potential expanded indications as well as the role of 
implantable cardioverter-defibrillators in the management of 
atrial and nonsustained ventricular tachyarrhythmias. 
Clinical Evaluation of Implantable 
Cardioverter-Defibrillator Devices 
Clinical evaluation of new implantable cardioverter- 
defibrillators currently requires equivalency testing. These 
devices are effective in preventing sudden cardiac death. A new 
device or modification of an existing device should be at least 
as effective and safe as devices that are currently available. 
Other goals can be envisioned, however, and it is important 
that a hypothesis be carefully developed for each planned 
clinical evaluation. 
Pre-market release valuation of implantable cardioverter- 
defibrillators entails pilot study and main study components a
described above. Previous NASPE recommendations (1987 
and 1991) concerning minimum number of devices, number of 
centers, and duration of follow-up should be reviewed by the 
planning committee based on study design considerations and 
the hypothesis to be tested. 
Study Design for Clinical Evaluation 
Randomized or observational study designs can be appro- 
priate. In randomized clinical trials patients are randomly 
assigned to one or two treatment limbs, representing either 
two different implantable cardioverter-defibrillator devices or 
implantable cardioverter-defibrillator therapy versus an alter- 
native therapy. While often desirable, such trials may not 
always be feasible outside of a unique window of time follow- 
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ing introduction of a particular device. For example, random- 
ized clinical trials of transvenous versus epicardial lead systems 
might have been feasible when transvenous leads were first 
introduced. However, it would now be difficult to obtain 
medical or ethical support for such a randomized trial, given 
the known lower mortality accompanying implantation of 
transvenous leads. In contrast, an automatic atrial defibrillator 
system or a totally new source-output waveform still falls 
within the window of opportunity for a randomized clinical 
trial. 
The primary purpose of a limited observational evaluation 
of an implantable cardioverter-defibrillator is to demonstrate 
safety, with the assumption that strong experimental and 
possibly other clinical data exist to support efficacy or that 
efficacy of the new device can be shown to be equivalent to that 
of a market-released device. Such a study involves a single 
limb, namely, device treatment, and is observational, usually 
relying on clinically comparable historical rather than concur- 
rent controls. Adjustments for known predictors of outcome 
may be appropriate to minimize selection or temporal biases. 
The planning committee may recommend that no pre- 
market release study is necessary if it is deemed that a device 
innovation, although clinically advantageous, has minimal 
potential adverse effects on safety. An example is altered 
spatial configuration of generator components o reduce de- 
vice volume. 
Post-Market Release Surveillance 
Long-terra monitoring of the safety of a device after its 
commercial release requires post-market release surveillance 
studies. This type of study is best done with a registry or 
database. The major purpose of such a study is to locate and 
follow up device implantees and monitor them for premature 
component failure or other unexpected problems. The number 
of patients and duration for this type of surveillance is deter- 
mined by a calculation that allows detection of an event rate 
with a 95% confidence interval. A broad-based committee may 
be helpful for setting requirements for each individual study. 
Extended surveillance of patients enrolled in the study would 
allow for a long-term follow-up. If the study involves a wide 
spectrum of sites (high- and low-volume centers, academic and 
private practice settings), these patients would be a represen- 
tative cross section of device implantees. 
Study End Points" 
End points should be selected on the basis of the primary 
hypothesis and secondary objectives of each study. Precise 
definition of end points related to morbidity and mortality in 
implantable cardioverter-defibrillator studies have been delin- 
eated in a 1993 NASPE policy statement. Total mortality need 
not be the primary end point in all implantable cardioverter- 
defibrillator studies, although it should always be reported. 
Total mortality should be a required primary end point when a 
device is considered novel or modification of an existing device 
can have an important impact on mortality. It is suggested that 
the impact of the innovation equal or exceed aminimum level 
for a clinically important change in annual mortality in the 
study population. The planning committee should make an 
informed judgment as to whether this value might be exceeded 
in a given investigation. The task force recognizes that patient 
selection will determine the total mortality rate observed in the 
study. 
In accord with a recent policy statement from NASPE, the 
primary mortality end point for implantable cardioverter- 
defibrillator investigations i total mortality. Although sub- 
classes of mortality may be tabulated, study design should be 
based on estimates of total mortality. This is preferred because 
of the difficulty inherent in classifying mortality. The minimum 
duration of patient follow-up should be at least 1 year. 
Actuarial presentation f the results hould be encouraged. All 
reported proportions hould be presented with 95% confi- 
dence intervals. Sample sizes and other adjustments should be 
made by the data and safety monitoring board as the study 
unfolds. 
Efficacy of implantable cardioverter-defibrillators in termi- 
nating nonfatal arrhythmia events is expected to become 
increasingly important and should always be reported. Specific 
nonfatal event end points will be chosen largely based on the 
primary objective or hypothesis of the study and/or device 
modification. As with mortality, actuarial reporting should be 
encouraged, 95% confidence intervals hould be reported for 
proportions, and careful consideration should be given to 
whether events, patients, or both should be used to calculate 
proportions. 
Complications and safety data related to the device or the 
device implant should always be recorded. These may be 
categorized by type and may include surgical complications, 
appropriate/inappropriate therapies, programmer failures/ 
difficulties, and premature component failure. Actuarial anal- 
ysis of these data should be encouraged. Evaluation of quality 
of life (perceived symptoms, return to work, functional and 
psychological status) following application of a device is 
deemed important. Long-term evaluation of the end points 
should encompass the patient's baseline status. Patient recov- 
ery problems and perceptions of the impact of the implantable 
cardioverter-defibrillator arerecommended. 
Patient Selection 
Safety and efficacy of a new implantable cardioverter- 
defibrillator (or antiarrhythmic drug) are influenced by the 
patient population receiving such therapy. For example, sur- 
vival is likely to be better in patients with a left ventricular 
ejection fraction greater than 30% than in those with poorer 
left ventricular function. Various other clinical factors may 
have an impact on efficacy and complication rates during 
implantable cardioverter-defibrillator evaluation, including 
type of underlying heart disease, psychosocial c ass, and New 
York Heart Association functional class. Differences in event 
rates, which indirectly affect assessment of efficacy, must also 
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be considered. Given the multiple factors involved, it is critical 
that comparison groups be as clinically similar as possible to 
the implantable cardioverter-defibrillator treatment group and 
that adjustment for relevant covariates be considered. More- 
over, inclusion criteria may need to be broadened or new 
studies with different inclusion criteria may need to be de- 
signed to justify application of the safety and efficacy results 
observed in one particular patient population to a broader 
group of potential implantees. 
Innovation in Implantable 
Cardioverter-Defibrillators 
Physician-led innovation with commercially released e- 
vices or system components has traditionally complemented 
development of devices by broadening therapeutic applications 
for patient benefit. Clinical innovation iswidespread in cardio- 
vascular medicine and may result from ongoing scientific 
investigations or physician and patient requests for access to 
restricted technology. Such access is deemed necessary for 
patient benefit. 
In implantable cardioverter-defibrillator herapy, clinical 
improvisations have involved various innovations in surgical 
implant echnique and a "mix and match" approach to assem- 
bling approved components into new hardware configurations. 
Examples of the latter type of improvisation are the use of Y 
connectors to yoke together three or more epicardial patch 
electrodes in patients with high defibrillation thresholds, 
creation of a nonthoracotomy implantable cardioverter- 
defibrillator lead system in which an epicardial patch electrode 
is placed subcutaneously onthe chest wall and coupled with a 
transvenous spring electrode, and other hybrid transvenous 
implantable cardioverter-defibrillator systems formed by com- 
bining approved components from different manufacturers. 
Freedom for physicians to improvise with approved evice 
components and surgical techniques for patient benefit must 
be maintained. Investigators involved in such activities, how- 
ever, are responsible for informing patients as well as carefully 
studying such combinations and reporting their independent or 
cooperative xperience with improvised therapy. Moreover, 
recent guidelines require that, in the context of public forums, 
any "out of labeling" use of a commercially released evice (or 
component) be clearly indicated as such, with concomitant 
delineation of alternative, approved therapies. Formal mech- 
anisms must be developed for tracking long-term efficacy and 
possible complications of improvised medical devices. Finally, 
although not addressed here, future efforts are needed to deal 
with liability issues related to improvised therapy. 
Clinical Evaluation of Ablation Devices 
Evolution of Catheter Ablation 
Following the introduction of therapeutic catheter ablation 
with high energy shocks in 1981, its use became widespread, 
but at a measured pace because of both the perceived and 
demonstrated hazards of high energy shocks. Since the intro- 
duction of radiofrequency urrent as ablative energy to pro- 
duce relatively small circumscribed zones of necrosis, there has 
been a proliferation of radiofrequency atheter ablation pro- 
cedures and their applications. Growing use of this therapy in 
the past 5 years can be attributed primarily to two factors. First, 
it has been verified that application of radiofrequency urrent 
to the endocardium is safer than shocks. Experiments with 
animals established that small circumscribed lesions produced 
in mature myocardium were not accompanied by adverse 
consequences over short and intermediate p riods of follow- 
up. Shock-related complications of myocardial depression and 
postprocedural sudden death were not observed. Intracardiac 
application of radiofrequency urrent is less likely to cause 
rupture and tamponade, asevidenced by the safe delivery of 
radiofrequency current into the coronary sinus, unlike delivery 
of shock. Cumulative xperience with thousands of patients 
with supraventricular rhythmias has established that the risk 
of serious complications with radiofrequency catheter ablation 
is less than 3%, and mortality for the procedure iswell below 
0.5%. Exact assessment of these low morbidity and mortality 
rates will require more experience with many thousands of 
patients. Nonetheless, experience has verified that the acute 
risks are far less than those attendant on cardiac surgical 
procedures. 
Secondly, radiofrequency atheter ablation has exploited 
existing technology. Instruments for generating radiofrequency 
current are widely available and have been used in surgery for 
many years. Initially the current was delivered through stan- 
dard electrode catheters, which were later modified to increase 
the surface area of the electrode tip to produce slightly larger 
lesions. Subsequently radiofrequency generators have been 
adapted for use in radiofrequency catheter ablation, including 
the capacity for temperature monitoring. Catheters have also 
been designed to facilitate the location of the diverse targets 
for ablation. The novel aspects of radiofrequency atheter 
ablation have been in the realm of clinical procedural skills and 
data analysis rather than the technology used in such proce- 
dures. 
Study Designs for Catheter Ablation 
The types of trials appropriate for catheter ablation must be 
considered in light of the advanced stage of progress in this 
therapy. There is agreement in the cardiology community hat 
randomized trials for comparisons of most applications of 
radiofrequency atheter ablation with cardiac surgery are not 
necessary, ethical, or feasible. Comparisons with pharmaco- 
therapy by randomized trials to establish a preference for 
initial therapy have not yet been performed and should be 
considered. 
It is important to stress that the goals of radiofrequency 
catheter ablation and pharmacotherapy redifferent and their 
durations of application are widely disparate. Radiofrequency 
catheter ablation is effective in the intermediate rm with a 
brief period of application. The goal of radiofrequency cathe- 
ter ablation is the elimination of arrhythmogenic myocardium; 
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electrophysiological evidence of elimination or modification of 
the arrhythmogenic substrate is the criterion for efficacy. 
Pharmacotherapy is continuous and lifelong. Quality of life is 
a major end point in most applications of radiofrequency 
catheter ablation. The psychological impact of individual ther- 
apies is a paramount consideration. Radiofrequency atheter 
ablation produces relief of symptoms and improved quality of 
life in the intermediate ime range. It can be expected to have 
a higher short-term morbidity and mortality in most types of 
arrhythmias except when drugs with significant ventricular 
proarrhythmic or other frequent adverse ffects are used. The 
question to be addressed iswhether the outcome is worth the 
risk of the procedure when the disease is not fatal but impairs 
quality of life. Well-informed patients can and should answer 
this question for themselves. Accurate information about 
ablation procedure-related risk and benefit as well as long- 
term data on morbidity and mortality with suppressive phar- 
macotherapy are needed. Patients can then make enlightened 
personal decisions. Continued careful observation ofa growing 
patient population is sufficient o establish the appropriate role 
of catheter ablation in most forms of arrhythmias. 
Recommendations for Clinical Evaluation of 
Radiofrequency Catheter Ablation Devices 
New devices that do not involve radical departures in 
technology could be evaluated by testing ex vivo to assure 
compliance with prescribed standards and by limited observa- 
tional trials in vivo. In such limited trials, controlled compar- 
isons within the same population of severity, frequency, and 
drug therapy of the arrhythmia before and after radiofre- 
quency catheter ablation should be used. Electrophysiological 
evidence of elimination of arrhythmogenic t ssue by the abla- 
tive procedure should be required. Randomized clinical trials 
should be considered for novel and radical departures in 
catheter ablation devices. Such trials should be developed in 
accord with previously stated guidelines, ie, the pilot studies do 
not indicate a large treatment effect of the new technology and 
the natural history of the disorder is not fully characterized. If 
available, other standard catheter ablation methods hould be 
used in controlled comparisons. Hybrid ablation systems re- 
quire clinical evaluation under these guidelines. Use of abla- 
tion systems with approved components should be permitted. 
However, investigators are responsible for carefully studying 
these combinations and reporting their findings. Such data may 
be used to develop databases or registries for clinical surveil- 
lance. 
Rapid expansion of the field has yielded a substantial base 
of empirical information regarding efficacy and safety. The lack 
of randomized clinical trials reduces the accuracy of compar- 
isons with other forms of therapy. Both safety and efficacy are 
likely to improve at major centers. Long-term efficacy and 
safety can be accurately assessed only by mechanisms for 
long-term surveillance such as registries and databases. Such 
concerns as late effects of radiation exposure and late appear- 
ance of arrhythmias related to scars created by radioffequency 
current can be addressed by systematic acquisition of data. 
Patient Selection 
The therapeutic role of radiofrequency atheter ablation in 
various arrhythmias has been previously addressed by the 
North American Society of Pacing and Electrophysiology and 
the American College of Cardiology (1992 and 1994). There is 
a consensus among cardiologists hat radiofrequency atheter 
ablation is a preferable or acceptable alternative for initial 
therapy in symptomatic patients with bundle branch reentrant 
ventricular tachycardia, trioventricular reentrant tachycardia, 
and atrioventricular junctional reentrant tachycardia. It is an 
acceptable alternative for a wide variety of arrhythmias that 
are resistant to pharmacotherapy, including atrial tachycardia, 
atrial flutter, atrial fibrillation (atrioventricular junctional ab- 
lation), and idiopathic ventricular tachycardia originating in 
the right ventricular outflow tract or left ventricle (left septal or 
verapamil-sensitive ventricular tachycardia). Right ventricular 
outflow tract and left septal ventricular tachycardias re prom- 
ising candidates for radiofrequency atheter ablation as initial 
therapy, but more experience is required to make that recom- 
mendation. Radiofrequency catheter ablation in ventricular 
tachycardia associated with structural heart disease, in which it 
has been notably less efficacious (except for bundle branch 
reentrant tachycardia), is acceptable for drug refractory ven- 
tricular tachycardia or when implantable cardioverter- 
defibrillator or surgical ablation therapy is inappropriate ornot 
feasible. 
Summary 
The goal of radiofrequency atheter ablation and the cri- 
terion for efficacy is the elimination of arrhythmogenic myo- 
cardium. The application of radiofrequency current in the 
heart clearly results in lower morbidity and mortality rates than 
thoracic and cardiac surgical procedures in general, and com- 
parisons of therapy with radiofrequency atheter ablation and 
therapy with thoracic and cardiac surgical procedures in ran- 
domized clinical trials is unwarranted. Trials of radiofrequency 
catheter ablation versus medical or implantable cardioverter- 
defibrillator therapy may be indicated in certain conditions, 
such as ventricular tachycardia associated with coronary artery 
disease. Randomized trials are recommended for new and 
radical departures in technology that aim to accomplish the 
same goals as radiofrequency atheter ablation. Surveillance 
using registries and/or databases is necessary in the assessment 
of long-term safety and efficacy. 
Recommendations 
The task force, on behalf of the sponsoring organizations, 
recommends that clear goals for various types of antiarrhyth- 
mic device investigations be developed and that current meth- 
ods of clinical evaluation of devices be modified. Issues sur- 
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rounding clinical investigations--the intensity and method of 
study, the framing of the study question(s), duration, and role 
of the government, manufacturers, and clinical investigators-- 
and their relation to timely and appropriate patient care are of 
critical importance. It is recommended that this report initiate 
a long-term process to develop an improved understanding of 
regulatory requirements and how they can best be met by all 
participants. There is general agreement that flexibility in 
clinical evaluation studies and their management is desirable 
to avoid delays and rejections when results are presented to 
regulatory bodies. There is a need to streamline the process for 
introducing new technology and developing an accelerated 
mechanism(s) for significant advances. The evaluation process 
should be reevaluated from the standpoint of pediatric pa- 
tients, who are infrequently included in clinical evaluation 
studies. Finally, there is legitimate concern that often too little 
is known about he etficacy of devices once they are approved 
and in general use. The policy conference on which this 
statement is based also considered issues related to the cost of 
clinical trials and reimbursement issues concerning devices and 
services involved in the performance ofdevice trials. Although 
not discussed here, interim recommendations were made, and 
it was strongly suggested that these issues be resolved at a later 
stage. Clinical evaluations, because of their limited scope, are 
unlikely to identify all the possible adverse ffects of antiar- 
rhythmic devices. 
1. Develop a better understanding of the scientific require- 
ments for the conduct of valid clinical investigations whether 
performed for regulatory or clinical research purposes. As a 
minimum every investigation should have 
• A clearly defined hypothesis 
• A detailed, explicit methodology for the conduct of the 
investigation, including patient selection criteria, data 
elements, an independent safety monitoring roup, and 
specified end points for pilot and main studies 
• A randomized clinical trial when novel technology and/or 
indications are being evaluated. Randomized clinical 
trials are not needed when the treatment effect is large in 
pilot studies or the natural history of the disease is well 
characterized. 
2. Communication is needed among all parties before 
formal proposal and/or initiation of a clinical evaluation based 
on regulatory equirements. To facilitate such communication, 
it is recommended that the regulatory agency create a formal 
advisory committee and that this committee be charged with 
making recommendations concerning both the priority of the 
matter proposed for evaluation and study design. Timely and 
prospective review of clinical evaluation protocols for devices 
by regulatory bodies is necessary to assess adequacy of study 
design for meeting stated objectives. External peer review and 
input from independent clinical scientists is strongly recom- 
mended uring this process. Independent panels or working 
groups formed with professional organizations with interests in 
this area are appropriate and will be beneficial to investigators, 
sponsors, regulatory agencies, and, ultimately, patients in- 
volved in clinical studies. 
3. Consistent with patient safety and scientific rigor, the 
proposed clinical evaluation process for regulatory purposes 
should be as expeditious as possible. The clinical evaluation 
should be designed to facilitate and simplify the existing 
approaches. A pilot study and a larger main study with interim 
study evaluation could achieve this goal. An accelerated val- 
uation should be considered for technology offering significant 
new clinical benefits. 
4. Continued surveillance of antiarrhythmic device perfor- 
mance after approval is mandatory, and a more formal, 
structured process of long-term data collection and analysis 
should be developed. This objective can be partially achieved 
by selected post-market release surveillance studies. Registries 
and databases can provide significant additional information 
relative to device and system performance, patient safety, and 
a wide spectrum of clinical experience. A national effort should 
be made to foster such endeavors as independent entities. The 
task force recommends registration of devices in a national 
database, g, the European Registry of the Implantable Defi- 
brillator. This type of system facilitates long-term follow-up of 
clinical performance and provides important patient safety and 
etficacy information. 
5. Innovation by physicians with approved evices, compo- 
nents, and surgical techniques for patient benefit is highly 
desirable. Investigators involved in such activities are respon- 
sible for evaluating hybrid systems and reporting their experi- 
ence in a systematic manner. 
6. Estimated costs of a clinical investigation must be con- 
sidered as part of the overall investigation. These costs have 
been evaluated for pharmaceutical gents and should be 
assessed for antiarrhythmic devices. Particular attention 
should be given to the economic implications of high-cost 
design for small manufacturers. 
7. Support for research on antiarrhythmic devices used in 
clinical evaluations i inconsistent and often difficult o obtain. 
A general policy should be established for public and private 
payers concerning appropriate support for research services 
provided during an approved clinical evaluation. This support 
is in the interest of patient care and social responsibility for the 
goal of public health. The task force recognizes that clinically 
beneficial device applications may become standard clinical 
practice based on investigator-initiated clinical research alone. 
Reimbursement decisions hould be determined by scientific 
review of existing clinical data with respect o clinical efficacy 
and patient safety. 
8. Continued interaction among the interested organiza- 
tions is highly desirable. Periodic review and discussions using 
mechanisms such as the task force will identify issues for 
further action and resolution. 
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